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Xenon is one of noble gases and has been recognized as an anesthetic for more than 50 years. Xenon possesses
many of the characteristics of an ideal anesthetic, but it is not widely applied in clinical practice mainly because of
its high cost. In recent years, numerous studies have demonstrated that xenon as an anesthetic can exert
neuroprotective and cardioprotective effects in different models. Moreover, xenon has been applied in the
preconditioning, and the neuroprotective and cardioprotective effects of xenon preconditioning have been
investigated in a lot of studies in which some mechanisms related to these protections are proposed. In this review,
we summarized these mechanisms and the biological effects of xenon preconditioning.
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very similar properties: they are all odorless, colorless,
monatomic gases with very low chemical reactivity
under standard conditions. The six noble gases occur-
ring naturally are helium (He), neon (Ne), argon (Ar),
krypton (Kr), xenon (Xe), and the radioactive radon (Rn)
[1]. Among these noble gases, xenon is the most fre-
quently investigated and widely applied in medicine.
Xenon has been used as an anesthetic [2], to treat brain
and heart injuries due to its neuroprotection and cardio-
protection [3,4] and in single photon emission computed
tomography (SPECT) [5].
Preconditioning is a process by which an organism’s ex-
posure to a stress/stimulus permits it to decrease cellular
damage or death when exposed to a subsequent greater or
more sustained stress. To date, a large number of strategies
have been developed for preconditioning such as lipopoly-
saccharide, heat and seizure, hypoxia and hyperoxia [6]. In
this brief review, we introduce the protective effects of
xenon preconditioning, not the xenon treatment.
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reproduction in any medium, provided the or1898. Xenon derives its name from the Greek word for
“stranger” [7]. Xenon is a trace gas in Earth’s atmosphere
and much more expensive than the lighter noble gases
due to its very low concentration in air (0.5 ppm) [2]. It
is inert to most common chemical reactions because the
outer valence shell contains eight electrons.
To date, xenon has been commercially used for lasers,
high intensity lamps, flash bulbs, jet propellant in the
aerospace industry, X-ray tubes, and in medicine [7].
In medicine, xenon has been used experimentally in
clinical anesthetic practice for more than 50 years. As a
general anesthetic, xenon possesses many advantages. For
example, its blood-gas partition coefficient is extremely
small (0.115), which results in a rapid onset and offset of its
action. It lacks teratogenicity and can produce profound
analgesia which thereby inhibits the surgery induced
hemodynamic and catecholamine responses. It is also a
potent hypnotic and does not produce hemodynamic de-
pression because it at least in part has no influence on
some important ion channels [2,7]. In addition, it has been
confirmed that xenon can confer neuroprotective [3] and
cardioprotective [4,8] effects. Unlike nitrous oxide (N2O),
xenon is not a greenhouse gas and so it is also viewed as
environmentally friendly [9]. Xenon that is vented into the
atmosphere is being returned to its original source, and
thus environmental pollution is unlikely. However, its rela-
tively high cost has precluded its more widespread clinical
use.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Liu et al. Medical Gas Research 2013, 3:3 Page 2 of 5
http://www.medicalgasresearch.com/content/3/1/3Mechanisms underlying bioeffects of xenon
Numerous studies have been conducted to investigate the
mechanisms of xenon’s bioeffects. Xenon can potently
inhibit the N-methyl-D-aspartate (NMDA) receptors non-
competitively, with little effect on the γ-aminobutyric acid
A (GABAA) receptor and non-NMDA glutamatergic re-
ceptor [10]. In the study of Yamakura and Harris, their
results showed N2O (0.58 atmosphere [atm]) and xenon
(0.46 atm) exhibited similar effects on various receptors,
and the NMDA receptors, and nACh receptors com-
posed of β2 subunits are likely targets for NO and
xenon [11]. In addition, xenon (and NO) has been
reported to competitively inhibit the 5-hydroxytryptamine
receptor 3A (5HT3A receptor) expressed in the xenopus
oocytes [12] but this has yet to be confirmed in mamma-
lian cells.
In addition, the xenon induced anesthesia is related to
the inhibition of the calcium ATPase pump on the cell
membrane of synapses [13], which results from a con-
formational change when xenon binds to nonpolar sites
inside the protein [14], and the non-specific interactions
between the xenon and the lipid membrane [15].
Mechanisms of protective effects of xenon
preconditioning
Cardioprotection, neuroprotection, renoprotective and
endothelial protection
In 2005, a German group found that exposure to 70%
xenon 45 min before myocardial ischemia could confer
cardioprotection in a rat model, in which the activation
of ε isoform of protein kinase C and its downstream tar-
get p38 mitogen-activated protein kinase (MAPK) is a
central molecular mechanism [16]. Eight months later,
the same group preconditioned rats with same methods,
but hearts without experiencing ischemia/reperfusion
were collected for detection. Their results demonstrated
that xenon preconditioning enhanced the translocation
of heat shock protein 27 (HSP27) to the particulate
fraction and increased F-actin polymerization and acti-
vated MAPKAPK-2 and HSP27 downstream of PKC and
p38 MAPK. Moreover, F-actin and pHSP27 were coloca-
lized after xenon preconditioning. Their findings link
xenon preconditioning to the cytoskeleton, revealing
new insights into the mechanisms of xenon precondi-
tioning in vivo [17]. In another study of Weber et al., they
found xenon preconditioning increased the translocation
of PKC-ε to membrane regions, and the mitochondrial ad-
enosine triphosphate (ATP) dependent potassium (KATP)
channels and 30 phosphatidylinositol-dependent kinase-1
(PDK-1) located upstream of PKC-ε and were crucial for
the activation of PKC-ε [18]. In addition, they noted ERK
1/2, but not JNK, was also a mediator of xenon precondi-
tioning [19]. A group in the USA found the cardioprotec-
tion of xenon preconditioning was attributed to thephosphorylation of Akt, glycogen synthase kinase 3 β
(GSK-3β), preservation of mitochondrial function, and
inhibition of Ca2+-induced mitochondrial permeability
transition (MPT) pore opening (Table 1) [20].
The neuroprotection of xenon preconditioning was
attributed to the transcription of activity-dependent neu-
roprotective protein (ADNP) in neonatal rats [21], the
opening of plasmalemmal KATP channels in neuronal-
glial cocultures [22] and a reduction in the plasma IL-1β
and an up-regulation of hippocampal HSP72 in the
surgery and/or isoflurane induced postoperative cogni-
tive decline (POCD) model [23]. Moreover, the neuro-
protection of xenon preconditioning was independent of
gender in mouse transient middle cerebral artery occlu-
sion model [24].
In the study of Ma et al., the xenon preconditioning
was found to be a natural inducer of hypoxia-inducible
factor (HIF-1α) [24,25]. Xenon preconditioning can acti-
vate HIF-1α and its downstream effectors erythropoietin
(EPO) and vascular endothelial growth factor (VEGF) in
a time-dependent manner in the kidneys in vivo and
in vitro [25,26].
In the human umbilical vein endothelial cells, xenon
preconditioning was found to prevent tumor necrosis
factor-α (TNF-α) induced mRNA and protein expression
of intracellular cell adhesion molecule 1 (ICAM-1) and vas-
cular cell adhesion molecule 1 (VCAM-1) and decreased
the TNF-α induced transcriptional activity of nuclear fac-
tor κB (NF-κB), but had no effect on the TNF-α induced
E-selectin expression [27].
Contribution of anesthetic property of xenon to
protective effects
Studies also revealed that preconditioning with other
noble gases without anesthetic properties could exert
protective effect [28,29]. These findings supported the
contention that the protection of preconditioning with
noble gases was independent of the anesthetic properties
per se. However, the protective effect of preconditioning
with other noble gases was not found in the human
tubular kidney cells, and even helium by comparison sig-
nificantly enhanced the cell injury [26]. Additionally, in
a study of Baumert et al., they did not confirm the cardi-
oprotective effect of brief, intermittent xenon precondi-
tioning, but the xenon anesthesia (xenon 70%, continued
before and after myocardial ischemia) exert protective
effect on myocardial ischemia [30]. Moreover, the xenon
exposure induced gene expression profile was also
found to be different from that following N2O (another
anesthetic) exposure [31].
Late protective effect of xenon preconditioning
In previous studies, pharmacological preconditioning
not only produces early protection but induces late
Table 1 Mechanisms of protective effects of xenon preconditioning
Mechanisms underlying protective effect of xenon preconditioning Organ protection
Activation of PKC-ε isoform and p38 MAPK [16] Cardioprotection
HSP27 translocation, F-actin polymerization, activation of MAPKAPK-2, PKC and p38 MAPK [17] Cardioprotection
PKC-ε translocation, mitochondrial ATP dependent KATP channels, PDK-1 [18] Cardioprotection
ERK 1/2 [19] Cardioprotection
Phosphorylation of Akt and GSK-3β, preservation of mitochondrial function, and inhibition of
Ca2+-induced MPT pore opening [20]
Cardioprotection
ADNP transcription [21] Neuroprotection
Opening of plasmalemmal KATP channels [22] Neuroprotection
Plasma IL-1β reduction and hippocampal HSP72 increase [23] Neuroprotection
HIF-1α, EPO and VEGF [24-26] Renoprotection
Reduction in ICAM-1, VCAM-1 and NF-κB [27] Protection on
endothelial cells
COX-2 activity [32] Cardioprotection
Enhanced phosphorylated cyclic adenosine monophosphate response element binding protein
signaling [33]
Neuroprotection
pCREB-regulated synthesis of proteins [34] Neuroprotection
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tioning [24,32-34]. The late myocardial protective effect
of xenon preconditioning was found to be closely rela-
ted to the cyclooxygenase-2 (COX-2) activity because
inhibition of COX-2 abolished this cardioprotective ef-
fect and the mRNA and protein expression of COX-2
remained unchanged following xenon preconditioning
[32], the enhanced phosphorylated cyclic adenosine
monophosphate response element binding protein sig-
naling [33] and the phosphorylated cAMP-response
element binding protein (pCREB)-regulated synthesis of
proteins that promote survival against neuronal injury
(Table 1) [33,34].
Comparisons of xenon preconditioning with other
strategies for preconditioning
Investigators also compared the protective effects of xenon
preconditioning with those of ischemia, anesthetic(s) and
hypoxia preconditioning. In the experimental myocardial
infarction model, results showed combined isoflurane/
xenon preconditioning reduced infarct size but not more
than isoflurane alone. Ischemic preconditioning was more
effective than the anesthetics [35]. In the rat N2O- and
isoflurane-induced neuroapoptosis model, xenon precon-
ditioning was found to prevent N2O oxide- and isoflurane-
induced neuroapoptosis (in vivo and in vitro) and cognitive
deterioration (in vivo). However, N2O - and isoflurane-
induced neuroapoptosis was exacerbated by hypoxic pre-
treatment. N2O pretreatment had no effect [36]. In the
study of Baumert et al., myocardial infarct size was
reduced by ischemic preconditioning but less so by xenon
anesthesia, and brief, intermittent exposure to xenon be-
fore myocardial ischemia did not reduce myocardial infarctsize [30]. However, in the study of Weber et al., ischemic
preconditioning induced by 3 × 5 min coronary artery oc-
clusion reduced infarct size to a similar extent like
anesthetic induced preconditioning [16].
Conclusion and perspectives
Although the anesthetic properties of xenon have been
known for more than 50 years and the neuroprotection
and cardioprotection of xenon demonstrated for more
than 10 years, xenon preconditioning is still in its infant
stage. The neuroprotective and cardioprotective effects
of xenon preconditioning have been confirmed in the
majority of studies, but clinical studies have not been
reported. In addition, numerous signaling pathways and a
large amount of molecules have been shown to involve in
the protective effects of xenon preconditioning, but the
relative contribution of each pathway or molecule is un-
clear to the protective effects of xenon preconditioning.
As shown above, the cost of xenon for anesthesia and
treatment is high due to the large amount of xenon
used, which is the major factor limiting the wide applica-
tion of xenon. However, in the available experiments on
xenon preconditioning, xenon was used in combination
with oxygen at a ratio of 7:3 (v/v), and preconditioning
was done with 3 cycles of xenon/oxygen administered
for 5 min periods [20] or for up to 20 min [23]. If the
protection of this strategy is confirmed, the cost of
xenon may be significantly reduced as compared to that
in the anesthesia and treatment. With the development
of technology, closed-circuit xenon delivery is intro-
duced. In the study of Chakkarapani et al., they reported
that the xenon consumption was minimal (<$2/h at $10/
L) when the gas exchange was maintained [37]. Thus,
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more, xenon is not flammable and can be easily applied
at bedside. Thus, we postulate that xenon precondition-
ing may become an alternative strategy for the preven-
tion of diseases or injuries.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Tao HY and Sun XJ outlined this review; Liu WW, Liu Y, Chen H and Liu K
searched the database and summarized the findings; Liu WW and Liu Y
drafted this manuscript; Tao HY and Sun XJ revised this review. All authors
read and approved the final manuscript
Acknowledgement
This study was partially supported by the National Natural Science
Foundation of China (No. 81000493/H0906).
Author details
1Department of Diving Medicine, Secondary Medical University, No 800
Xiangyin Road, Yangpu District, Shanghai 200433, People’s Republic of China.
2Department of General Surgery, 411 Hospital, No 15 Dongjiangwan Road,
Hongkou District, Shanghai 200081, People’s Republic of China. 3Institute of
Nautical Medicine, Nantong University, Jiangsu 226019, People’s Republic of
China. 4Department of Pathology, Yantaishan Hospital, Yantai, Shandong
264000, People’s Republic of China.
Received: 9 November 2012 Accepted: 25 December 2012
Published: 10 January 2013
References
1. Noble gas: http://en.wikipedia.org/wiki/Noble_gas.
2. Jordan BD, Wright EL: Xenon as an anesthetic agent. AANA J 2010,
78:387–392.
3. Banks P, Franks NP, Dickinson R: Competitive inhibition at the glycine site
of the N-methyl-D-aspartate receptor mediates xenon neuroprotection
against hypoxia-ischemia. Anesthesiology 2010, 112:614–622.
4. Pagel PS: Cardioprotection by noble gases. J Cardiothorac Vasc Anesth
2010, 24:143–163.
5. Suga K, Kawakami Y, Yamashita T, Zaki M, Matsunaga N: Characterization of
133Xe gas washout in pulmonary emphysema with dynamic 133Xe SPECT
functional images. Nucl Med Commun 2006, 27:71–80.
6. Liu W, Khatibi N, Sridharan A, Zhang JH: Application of medical gases in
the field of neurobiology. Med Gas Res 2011, 1:13.
7. Sanders R, Franks N, Maze M: Xenon: no stranger to anaesthesia.
Br J Anaesth 2003, 91:709–717.
8. Preckel B, Müllenheim J, Moloschavij A, Thämer V, Schlack W: Xenon
administration during early reperfusion reduces infarct size after
regional ischemia in the rabbit heart in vivo. Anesth Analg 2000,
91:1327–1332.
9. Goto T, Nakata Y, Morita S: Will xenon be a stranger or a friend? the cost,
benefit, and future of xenon anesthesia. Anesthesiology 2003, 98:1–2.
10. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR: How does xenon
produce anesthesia? Nature 1998, 396:324.
11. Yamakura T, Harris RA: Effects of gaseous anesthetics nitrous oxide and
xenon on ligand-gated ion channels. Comparison with isoflurane and
ethanol. Anesthesiology 2000, 93:1095–1101.
12. Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T: The diverse actions
of volatile and gaseous anesthetics on human-cloned 5-
hydroxytryptamine 3 receptors expressed in Xenopus oocytes.
Anesthesiology 2002, 96:699–704.
13. Franks JJ, Horn JL, Janicki PK, Singh G: Halothane, isoflurane, xenon, and
nitrous oxide inhibit calcium ATPase pump activity in rat brain synaptic
plasma membranes. Anesthesiology 1995, 82:108–117.
14. Lopez MM, Kosk-Kosicka D: How do volatile anesthetics inhibit
Ca2+-ATPases? J Biol Chem 1995, 270(47):28239–28245.
15. Xu Y, Tang P: Amphiphilic sites for general anesthetic action? Evidence
from 129Xe-[1H] intermolecular nuclear Overhauser effects. Biochim
Biophys Acta 1997, 1323(1):154–162.16. Weber NC, Toma O, Wolter JI, Obal D, Müllenheim J, Preckel B, Schlack W:
The noble gas xenon induces pharmacological preconditioning in the
rat heart in vivo via induction of PKC-epsilon and p38 MAPK.
Br J Pharmacol 2005, 144:123–132.
17. Weber NC, Toma O, Wolter JI, Wirthle NM, Schlack W, Preckel B:
Mechanisms of xenon- and isoflurane-induced preconditioning - a
potential link to the cytoskeleton via the MAPKAPK-2/HSP27 pathway.
Br J Pharmacol 2005, 146:445–455.
18. Weber NC, Toma O, Damla H, Wolter JI, Schlack W, Preckel B: Upstream
signaling of protein kinase C-epsilon in xenon-induced pharmacological
preconditioning. Implication of mitochondrial adenosine triphosphate
dependent potassium channels and phosphatidylinositol dependent
kinase-1. Eur J Pharmacol 2006, 539:1–9.
19. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B: Xenon
preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54
MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth 2006, 97:298–306.
20. Mio Y, Shim YH, Richards E, Bosnjak ZJ, Pagel PS, Bienengraeber M: Xenon
preconditioning: the role of prosurvival signaling, mitochondrial
permeability transition and bioenergetics in rats. Anesth Analg 2009,
108:858–866.
21. Cattano D, Valleggi S, Ma D, Kastsiuchenka O, Abramo A, Sun P, Cavazzana
AO, Natale G, Maze M, Giunta F: Xenon induces transcription of ADNP in
neonatal rat brain. Neurosci Lett 2008, 440:217–221.
22. Bantel C, Maze M, Trapp S: Neuronal preconditioning by inhalational
anesthetics: evidence for the role of plasmalemmal adenosine
triphosphate-sensitive potassium channels. Anesthesiology 2009,
110:986–995.
23. Vizcaychipi MP, Lloyd DG, Wan Y, Palazzo MG, Maze M, Ma D: Xenon
pretreatment may prevent early memory decline after isoflurane
anesthesia and surgery in mice. PLoS One 2011, 6:e26394.
24. Limatola V, Ward P, Cattano D, Gu J, Giunta F, Maze M, Ma D: Xenon
preconditioning confers neuroprotection regardless of gender in a
mouse model of transient middle cerebral artery occlusion. Neuroscience
2010, 165:874–881.
25. Ma D, Lim T, Xu J, Tang H, Wan Y, Zhao H, Hossain M, Maxwell PH, Maze M:
Xenon preconditioning protects against renal ischemic-reperfusion
injury via HIF-1alpha activation. J Am Soc Nephrol 2009, 20:713–720.
26. Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases
on oxygen and glucose deprived injury in human tubular kidney cells.
Exp Biol Med (Maywood) 2010, 235:886–891.
27. Weber NC, Kandler J, Schlack W, Grueber Y, Frädorf J, Preckel B: Intermitted
pharmacologic pretreatment by xenon, isoflurane, nitrous oxide, and the
opioid morphine prevents tumor necrosis factor alpha-induced adhesion
molecule expression in human umbilical vein endothelial cells.
Anesthesiology 2008, 108:199–207.
28. Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, Weihrauch
D, Warltier DC, Pratt PF Jr: Noble gases without anesthetic properties
protect myocardium against infarction by activating prosurvival
signaling kinases and inhibiting mitochondrial permeability transition
in vivo. Anesth Analg 2007, 105:562–569.
29. Pagel PS, Krolikowski JG, Pratt PF Jr, Shim YH, Amour J, Warltier DC,
Weihrauch D: The mechanism of helium-induced preconditioning: a
direct role for nitric oxide in rabbits. Anesth Analg 2008, 107:762–768.
30. Baumert JH, Hein M, Gerets C, Baltus T, Hecker KE, Rossaint R: The effect of
xenon anesthesia on the size of experimental myocardial infarction.
Anesth Analg 2007, 105:1200–1206.
31. Valleggi S, Cavazzana AO, Bernardi R, Ma D, Natale G, Maze M, Cattano D,
Giunta F: Xenon up-regulates several genes that are not up-regulated by
nitrous oxide. J Neurosurg Anesthesiol 2008, 20:226–232.
32. Weber NC, Frässdorf J, Ratajczak C, Grueber Y, Schlack W, Hollmann MW,
Preckel B: Xenon induces late cardiac preconditioning in vivo: a role for
cyclooxygenase 2? Anesth Analg 2008, 107:1807–1813.
33. Luo Y, Ma D, Ieong E, Sanders RD, Yu B, Hossain M, Maze M: Xenon and
sevoflurane protect against brain injury in a neonatal asphyxia model.
Anesthesiology 2008, 109:782–789.
34. Ma D, Hossain M, Pettet GK, Luo Y, Lim T, Akimov S, Sanders RD, Franks NP,
Maze M: Xenon preconditioning reduces brain damage from neonatal
asphyxia in rats. J Cereb Blood Flow Metab 2006, 26:199–208.
35. Baumert JH, Hein M, Gerets C, Baltus T, Hecker KE, Rossaint R: The effect of
xenon on isoflurane protection against experimental myocardial
infarction. J Cardiothorac Vasc Anesth 2009, 23:614–618.
Liu et al. Medical Gas Research 2013, 3:3 Page 5 of 5
http://www.medicalgasresearch.com/content/3/1/336. Shu Y, Patel SM, Pac-Soo C, Fidalgo AR, Wan Y, Maze M, Ma D: Xenon
pretreatment attenuates anesthetic-induced apoptosis in the developing
brain in comparison with nitrous oxide and hypoxia. Anesthesiology 2010,
113:360–368.
37. Chakkarapani E, Thoresen M, Hobbs CE, Aquilina K, Liu X, Dingley J: A
closed-circuit neonatal xenon delivery system: a technical and practical
neuroprotection feasibility study in newborn pigs. Anesth Analg 2009,
109:451–460.
doi:10.1186/2045-9912-3-3
Cite this article as: Liu et al.: Xenon preconditioning: molecular
mechanisms and biological effects. Medical Gas Research 2013 3:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
